If you know the story about Goodman selling Paladin ... it was something like ... if he couldn't run it anymore (after the bike accident) then he didn't to own it. That's when he put it up for sale.
By the time an offer came in, Goodman was in recovery mode and things were getting better. He didn't really want to sell it as his health improved but he was made an offer he just couldn't refuse.
Then ... I think there was a trigger that make Goodman want to start another pharma company.
In pricing out Paladin, Goodman said that Endo could have the drug IMPAVIDO but that it would cost them. The CEO of Endo (at the time - before he got the boot) said he didn't want IMPAVIDO. That drug eventually became the catalyst for Knight Therapeutics. In the future, it earned $140M CAD when we recieved a PRV from the FDA and in turn sold the PVR to Gilead.
There may have been another trigger at the time of the Paladin sale ...
ENDO had no intention of keeping Goodman on. That was likely expected but I think it got Goodman thinking. He was getting better and he didn't want to hang it up just yet.
At some point, I do remember Goodman being very critical of ENDO's approach to debt accumulation for the purpose of acquiring and I recall him getting under the CEO's skin. I don't know the order of how/when it all happened but I know Goodman eventually had something to prove ... that he could do it again. Better than the first time.
Will see! We certainly are looking good between $200MM and $300MM in sales now.
https://www.bizjournals.com/philadelphia/news/2022/08/10/endo-malvern-interest-payment-opioids-bankruptcy.html